Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 31, 2009

PsychoGenics to Assess AstraZeneca Candidates for Treating Central Nervous System Disorders

  • AstraZeneca signed on PsychoGenics to evaluate a number of its drug candidates for their potential to treat psychiatric disorders. The company will use its high-throughput drug discovery platforms that combine behavioral neurobiology with robotics, bioinformatics, and computer vision.

    PsychoGenics will receive research payments and milestones commensurate with the stage of development. The company is also entitled to royalties on any future sales.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »